CN101343322A - A rapid immunization method for preparation of domoic acid monoclonal antibody - Google Patents
A rapid immunization method for preparation of domoic acid monoclonal antibody Download PDFInfo
- Publication number
- CN101343322A CN101343322A CNA2008100511317A CN200810051131A CN101343322A CN 101343322 A CN101343322 A CN 101343322A CN A2008100511317 A CNA2008100511317 A CN A2008100511317A CN 200810051131 A CN200810051131 A CN 200810051131A CN 101343322 A CN101343322 A CN 101343322A
- Authority
- CN
- China
- Prior art keywords
- antigen
- mouse
- adjuvant
- day
- rouge
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 22
- 230000003053 immunization Effects 0.000 title claims abstract description 20
- 238000002649 immunization Methods 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- VZFRNCSOCOPNDB-AJKFJWDBSA-N domoic acid Chemical compound OC(=O)[C@@H](C)\C=C\C=C(/C)[C@H]1CN[C@H](C(O)=O)[C@H]1CC(O)=O VZFRNCSOCOPNDB-AJKFJWDBSA-N 0.000 title claims abstract description 17
- VZFRNCSOCOPNDB-UHFFFAOYSA-N domoic acid Natural products OC(=O)C(C)C=CC=C(C)C1CNC(C(O)=O)C1CC(O)=O VZFRNCSOCOPNDB-UHFFFAOYSA-N 0.000 title claims abstract description 17
- VZFRNCSOCOPNDB-OXYNIABMSA-N isodomoic acid D Natural products CC(C=C/C=C(/C)C1CNC(C1CC(=O)O)C(=O)O)C(=O)O VZFRNCSOCOPNDB-OXYNIABMSA-N 0.000 title claims abstract description 17
- 239000000427 antigen Substances 0.000 claims abstract description 31
- 108091007433 antigens Proteins 0.000 claims abstract description 31
- 102000036639 antigens Human genes 0.000 claims abstract description 31
- 239000002671 adjuvant Substances 0.000 claims abstract description 23
- 241000699670 Mus sp. Species 0.000 claims abstract description 13
- 210000002966 serum Anatomy 0.000 claims abstract description 10
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 claims abstract description 6
- 210000004027 cell Anatomy 0.000 claims description 39
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 28
- 239000000243 solution Substances 0.000 claims description 16
- 239000007924 injection Substances 0.000 claims description 12
- 238000002347 injection Methods 0.000 claims description 12
- 210000004698 lymphocyte Anatomy 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
- 239000012980 RPMI-1640 medium Substances 0.000 claims description 5
- 239000006285 cell suspension Substances 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 3
- 210000005252 bulbus oculi Anatomy 0.000 claims description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 2
- 229910052802 copper Inorganic materials 0.000 claims description 2
- 239000010949 copper Substances 0.000 claims description 2
- 210000003205 muscle Anatomy 0.000 claims description 2
- 239000013641 positive control Substances 0.000 claims description 2
- 238000004659 sterilization and disinfection Methods 0.000 claims description 2
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 claims 7
- 238000004945 emulsification Methods 0.000 claims 4
- 230000024835 cytogamy Effects 0.000 claims 2
- 230000000527 lymphocytic effect Effects 0.000 claims 1
- 235000015097 nutrients Nutrition 0.000 claims 1
- 238000004321 preservation Methods 0.000 claims 1
- 230000001954 sterilising effect Effects 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 238000001514 detection method Methods 0.000 abstract description 11
- 210000001165 lymph node Anatomy 0.000 abstract description 7
- 230000007910 cell fusion Effects 0.000 abstract description 4
- 238000005516 engineering process Methods 0.000 abstract description 4
- 210000003141 lower extremity Anatomy 0.000 abstract description 4
- 210000002683 foot Anatomy 0.000 description 13
- 206010003445 Ascites Diseases 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 239000001963 growth medium Substances 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 210000004408 hybridoma Anatomy 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- 208000005374 Poisoning Diseases 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- 231100000572 poisoning Toxicity 0.000 description 6
- 230000000607 poisoning effect Effects 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 239000000047 product Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 241000195493 Cryptophyta Species 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 231100000765 toxin Toxicity 0.000 description 4
- 208000000044 Amnesia Diseases 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 210000000683 abdominal cavity Anatomy 0.000 description 3
- 238000005251 capillar electrophoresis Methods 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000004303 peritoneum Anatomy 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000005138 cryopreservation Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 235000015170 shellfish Nutrition 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 208000031295 Animal disease Diseases 0.000 description 1
- 241000206761 Bacillariophyta Species 0.000 description 1
- 241000237519 Bivalvia Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical class OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 241000237536 Mytilus edulis Species 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- VLSMHEGGTFMBBZ-UHFFFAOYSA-N alpha-Kainic acid Natural products CC(=C)C1CNC(C(O)=O)C1CC(O)=O VLSMHEGGTFMBBZ-UHFFFAOYSA-N 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 235000020639 clam Nutrition 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- VLSMHEGGTFMBBZ-OOZYFLPDSA-N kainic acid Chemical compound CC(=C)[C@H]1CN[C@H](C(O)=O)[C@H]1CC(O)=O VLSMHEGGTFMBBZ-OOZYFLPDSA-N 0.000 description 1
- 229950006874 kainic acid Drugs 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 231100000863 loss of memory Toxicity 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 235000020638 mussel Nutrition 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
一种快速制备软骨藻酸单克隆抗体的免疫方法,涉及免疫安全检测技术中单克隆抗体的制备,其步骤为,取8周龄雄性BALB/C小鼠,第一天使用弗氏完全佐剂乳化完全抗原,抗原佐剂比6∶4,注射后肢足垫18-22μl/脚,第三或四天待应激状态降低,使用弗氏不完全佐剂乳化,抗原佐剂比6∶4,注射后肢足垫27-33μl/脚,第14-16天检测血清效价,效价达到1∶3200以上,取两后腿腘淋巴结进行细胞融合。本免疫方案与传统方法相比,具有免疫速度快,至少节省1个月的时间,抗原用量少,从而有效地降低单克隆抗体制备的成本。An immunization method for rapidly preparing domoic acid monoclonal antibody, which involves the preparation of monoclonal antibody in the immune safety detection technology. The steps are as follows: take 8-week-old male BALB/C mice and use Freund's complete adjuvant on the first day Emulsify the complete antigen, the antigen-adjuvant ratio is 6:4, inject 18-22 μl/foot on the footpad of the hind limb, and wait for the stress state to decrease on the third or fourth day, emulsify with Freund's incomplete adjuvant, the antigen-adjuvant ratio is 6:4, Inject 27-33 μl/foot into the foot pads of the hind limbs, and test the serum titer on the 14th to 16th day, and the titer is above 1:3200, and the popliteal lymph nodes of the two hind legs are taken for cell fusion. Compared with the traditional method, this immunization scheme has a faster immunization speed, saves at least one month of time, and uses less antigen, thereby effectively reducing the cost of monoclonal antibody preparation.
Description
[技术领域] [technical field]
本发明涉及免疫安全检测技术中单克隆抗体的制备,进一步讲涉及可应用于水产品及水环境中软骨藻酸单克隆抗体的制备。The invention relates to the preparation of a monoclonal antibody in immune safety detection technology, and further relates to the preparation of a domoic acid monoclonal antibody applicable to aquatic products and water environments.
[背景技术] [Background technique]
软骨藻酸(Domoic acid,DA)是主要由拟菱形藻属硅藻产生的一种谷氨酸和红藻酸的类似物,经食物链富集后,将对所在地区的生态环境造成严重影响,并引起动物发病和死亡,水中的蛤蜊、蚌类及鱼均可富集DA,人食用被污染的水产品即可引起中毒。DA的分子式为C5H21NO6,分子量311.34,纯品为无色晶体,对热稳定,熔点为223-224℃。易溶于水、稀酸和碱溶液中,微溶于甲醇和乙醇,不溶于石油醚和苯。产生DA的拟菱形藻是中国沿海普遍存在的藻类,并且是引发赤潮的重要藻类,在大连、青岛、黄海长江口、厦门港及南海各港湾都引起过赤潮。Domoic acid (DA) is an analogue of glutamic acid and kainic acid mainly produced by diatoms of the genus Pseudomonas. After being enriched in the food chain, it will have a serious impact on the ecological environment of the area. And cause animal disease and death, clams, mussels and fish in the water can be enriched in DA, human consumption of contaminated aquatic products can cause poisoning. The molecular formula of DA is C 5 H 21 NO 6 , the molecular weight is 311.34, the pure product is a colorless crystal, stable to heat, and the melting point is 223-224°C. Soluble in water, dilute acid and alkali solution, slightly soluble in methanol and ethanol, insoluble in petroleum ether and benzene. Pseudonitzia producing DA is a ubiquitous algae in the coastal areas of China, and is an important algae that causes red tides. Red tides have been caused in Dalian, Qingdao, the Yangtze River Estuary of the Yellow Sea, Xiamen Port and various harbors in the South China Sea.
DA是引起人类记忆缺失性中毒的致病因子。中毒症状包括胃肠道症状及神经系统症状,特别是记忆力的暂时丧失是此种中毒的特有症状。因此,DA中毒又称为“记忆丧失性中毒”。目前我国还没有水及水产品中DA的安全标准。加拿大规定的安全标准是□20μg/g贝类组织,这个标准也被其他一些国家采用。DA is the pathogenic factor causing amnesia poisoning in humans. Poisoning symptoms include gastrointestinal symptoms and neurological symptoms, especially the temporary loss of memory is a unique symptom of this poisoning. Therefore, DA poisoning is also called "memory loss poisoning". At present, there is no safety standard for DA in water and aquatic products in my country. The safety standard stipulated by Canada is □20μg/g shellfish tissue, and this standard has also been adopted by some other countries.
有关DA的检测方法主要是仪器分析法,包括高效液相色谱法(HPLC)和毛细管电泳法(CE)。HPLC已被澳大利亚规定为国家标准检测方法,加拿大、西班牙、丹麦、新西兰和美国等国家也采用HPLC检测浮游生物和贝类等代谢或蓄积的DA。毛细管电泳法是近几年发展起来的藻类毒素分离检测技术之一。免疫学检测法以其检测的稳定性、高灵敏性和速度快等优点在一些藻类毒素检测中得以广泛应用。The detection methods of DA are mainly instrumental analysis methods, including high performance liquid chromatography (HPLC) and capillary electrophoresis (CE). HPLC has been regulated by Australia as a national standard detection method, and countries such as Canada, Spain, Denmark, New Zealand and the United States also use HPLC to detect metabolized or accumulated DA in plankton and shellfish. Capillary electrophoresis is one of the techniques for the separation and detection of algal toxins developed in recent years. Immunological detection method has been widely used in the detection of some algae toxins due to its stability, high sensitivity and fast speed.
单克隆抗体的制备是建立免疫学检测方法的关键步骤之一。但由于藻毒素标准品价格昂贵、难以获得,至今国内尚未见DA单克隆抗体制备的报道。The preparation of monoclonal antibodies is one of the key steps in the establishment of immunological detection methods. However, due to the high price and difficulty in obtaining algae toxin standard products, there have been no reports on the preparation of DA monoclonal antibodies in China so far.
目前,单克隆抗体的制备多采用腹腔及皮下注射免疫方案。待被免疫小鼠血清效价达4×104以上后,取小鼠脾细胞与sp2/0细胞融合,有限稀释法克隆,ELISA筛选阳性杂交瘤细胞株,阳性细胞扩大培养后,小鼠腹水制备单克隆抗体。该方法已经是一项非常成熟的技术,广泛应用于食品及环境免疫安全检测技术中单克隆抗体的制备。但是,该免疫方法所需的免疫时间较长,至少需要4次以上的免疫后才能进行细胞融合,至少需1.5个月以上;对抗原的需求量大,一般需200-475μg/鼠。这大大地增加了单克隆抗体制备的成本,特别是对价格昂贵的抗原,如海洋生物毒素等,制备一株单克隆抗体需要数万元人民币。At present, the preparation of monoclonal antibodies mostly adopts intraperitoneal and subcutaneous injection immunization schemes. After the serum titer of the immunized mice reached 4× 104 or more, the splenocytes of the mice were fused with sp2/0 cells, cloned by limiting dilution, and the positive hybridoma cell lines were screened by ELISA. After the positive cells were expanded and cultured, the mouse ascites Preparation of monoclonal antibodies. This method is already a very mature technology, widely used in the preparation of monoclonal antibodies in food and environmental immune safety detection technology. However, the immunization time required by this immunization method is relatively long, requiring at least 4 times of immunization before cell fusion can take place, and at least 1.5 months; the demand for antigen is large, generally 200-475 μg/mouse. This greatly increases the cost of monoclonal antibody preparation, especially for expensive antigens, such as marine biotoxins, etc., tens of thousands of yuan is required to prepare a monoclonal antibody.
【发明内容】 【Content of invention】
本发明要解决的技术问题是提供一种快速制备软骨藻酸单克隆抗体的免方法,具有免疫速度快,所需抗原量少的特点,从而有效降低单克隆抗体制备的成本。The technical problem to be solved by the present invention is to provide a rapid immunization method for preparing domoic acid monoclonal antibody, which has the characteristics of fast immunization speed and small amount of antigen required, thereby effectively reducing the cost of monoclonal antibody preparation.
本发明解决技术问题所采用的方案采用如下步骤:The solution adopted by the present invention to solve technical problems adopts the following steps:
(1)取免疫动物为8周龄雄性BALB/C小鼠;(1) The immunized animals were 8-week-old male BALB/C mice;
(2)第一天使用弗氏完全佐剂乳化完全抗原,抗原佐剂比6∶4,注射后肢足垫18-22μl/脚,共36-44μl/鼠,抗原量为36-44μg/鼠;(2) On the first day, the complete antigen was emulsified with Freund's complete adjuvant, the antigen-adjuvant ratio was 6:4, and 18-22 μl/foot was injected into the hindlimb foot pad, a total of 36-44 μl/mouse, and the antigen amount was 36-44 μg/mouse;
(3)第三或四天待应激状态降低(可观察睾丸处状态,待肿大恢复正常)使用弗氏不完全佐剂乳化,抗原佐剂比6∶4,注射后肢足垫27-33μl/脚,共54-66μl/鼠。抗原量为54-66μg/鼠;(3) On the third or fourth day, when the stress state is reduced (the state of the testis can be observed, until the swelling returns to normal), emulsify with Freund's incomplete adjuvant, the ratio of antigen and adjuvant is 6:4, and inject 27-33 μl of the foot pad of the hind limb /foot, a total of 54-66μl/mouse. The amount of antigen is 54-66μg/mouse;
(4)第14-16天检测血清效价,效价达到1∶3200以上,取两后腿腘淋巴结进行细胞融合。(4) Serum titer was detected on the 14th to 16th day, and the titer reached more than 1:3200, and the popliteal lymph nodes of both hind legs were collected for cell fusion.
上述注射方法是采用1ml注射器,4.5号针头,在后足垫第二或三肉铺处进针,平行脚掌移动到脚掌中央处注射,注射完毕后停4-6秒钟,转动针头30度再出针,这样可避免抗原被压迫溢出皮肤。The above injection method is to use a 1ml syringe with a 4.5-gauge needle, insert the needle at the second or third meat shop of the rear foot pad, move parallel to the sole of the foot to the center of the sole of the foot for injection, stop for 4-6 seconds after the injection, turn the needle 30 degrees and then inject. The needle is removed so as to prevent the antigen from being pressed out of the skin.
首免14-16日腘淋巴结肿大明显,米粒大小,颜色白色透明,质地松软,将淋巴结研磨破碎可得到2×108个细胞。融合率为常规方法的10倍。On the 14th to 16th day of the first administration, the popliteal lymph nodes were obviously swollen, the size of rice grains, white and transparent in color, and soft in texture. Grinding and crushing the lymph nodes yielded 2×10 8 cells. The fusion rate is 10 times that of conventional methods.
采用本免疫方法所制备的单克隆抗体腹水效价可达4.8×105,亲和常数达2.9×108M-1,腹水抗体效价和亲和常数不低于传统免疫方法所得抗体。The ascites titer of the monoclonal antibody prepared by this immunization method can reach 4.8×10 5 , and the affinity constant can reach 2.9×10 8 M -1 .
本免疫方案与传统方法相比,具有免疫速度快,至少节省1个月的时间;所需抗原量少(仅需要100μg/鼠)。Compared with the traditional method, this immunization scheme has a faster immunization speed and saves at least one month; the amount of antigen required is less (only 100 μg/mouse).
本发明方法免疫时间短,抗原用量少,从而有效地降低单克隆抗体制备的成本。The method of the invention has short immunization time and less antigen consumption, thereby effectively reducing the cost of monoclonal antibody preparation.
[实施例1]试剂来源及完全抗原制备[Example 1] Reagent source and complete antigen preparation
聚乙二醇(polythylene glycol-4000,PEG)、RPMI1640培养基、透析袋、HAT选择性培养基、DA标准品、人IgG、牛血清白蛋白(OVA)、N-羟丁二酰亚胺、N,N双环乙烷碳二亚胺(N,N-dicyclohexylcarbodiimide,DCC)、N,N-二甲基甲酰胺(N,N-dimethyformamide,DMF)、福氏完全佐剂(FCA)、福氏不完全佐剂(FICA)、邻苯二胺(OPD)等购自Sigma公司;离心超滤管为MILLPORE产品;辣根过氧化物酶际记羊抗鼠IgG购于鼎国生物技术有限公司(北京),其它所用试剂均为国产分析纯。Polyethylene glycol (polythylene glycol-4000, PEG), RPMI1640 medium, dialysis bag, HAT selective medium, DA standard, human IgG, bovine serum albumin (OVA), N-hydroxysuccinimide, N, N-dicyclohexylcarbodiimide (N, N-dicyclohexylcarbodiimide, DCC), N, N-dimethylformamide (N, N-dimethylformamide, DMF), Freund's complete adjuvant (FCA), Freund's Incomplete adjuvant (FICA) and o-phenylenediamine (OPD) were purchased from Sigma; centrifugal ultrafiltration tubes were purchased from MILLPORE; horseradish peroxidase Jiji goat anti-mouse IgG was purchased from Dingguo Biotechnology Co. Beijing), and other reagents used were of domestic analytical grade.
采用活泼酯法制备完全抗原。偶联抗原DA-IgG(用于免疫)和DA-OVA(用于检测)具体制备方法如下:1mgDA、0.25mg N-羟丁二酰亚胺、0.6mg N,N双环乙烷碳二亚胺于80μLDMF中混均,室温搅拌2.5h,其中40μL反应液加入4mgIgG(溶于50μL 0.1mol/L硼酸缓冲液),另外40μL反应液加入4mgOVA(溶于50μL 0.1mol/L硼酸缓冲液),室温继续孵育2.5h,未反应的物质通过超滤离心去除,将偶联抗原用适当体积的硼酸缓冲液(pH8.2)溶起,使其浓度为1g/L,-80℃保存备用。The complete antigen was prepared by the active ester method. The specific preparation method of coupled antigen DA-IgG (for immunization) and DA-OVA (for detection) is as follows: 1mgDA, 0.25mg N-hydroxysuccinimide, 0.6mg N, N dicycloethanecarbodiimide Mix well in 80μL DMF, stir at room temperature for 2.5h, add 4mgIgG (dissolved in 50μL 0.1mol/L borate buffer) to 40μL reaction solution, and add 4mgOVA (dissolve in 50μL 0.1mol/L borate buffer solution) to the other 40μL reaction solution, at room temperature Continue to incubate for 2.5 hours, remove unreacted substances by ultrafiltration and centrifugation, dissolve the conjugated antigen with an appropriate volume of borate buffer (pH 8.2) to a concentration of 1 g/L, and store at -80°C for future use.
[实施例2]SP2/0细胞的复苏及扩大培养[Example 2] Recovery and expanded culture of SP2/0 cells
取出SP2/0细胞冻存管,立即放入装有40℃水的保温桶内,轻轻晃动,直至动存液完全溶解,要在1-2min内完成。将动存液移到15mL离心管,加入5mL培养液,轻轻吹均匀,1000rpm,5min,弃上清。用巴斯德吸管加入1管培养液,吹打均匀,移入50mL培养瓶内,再加入2吸管培养液,吹打均匀,分到2个新的50mL培养瓶内,这样就将一个冻存管细胞分到3个50mL培养瓶内。放于37℃含5%的二氧化碳培养箱中培养。24h后换液,每瓶4巴斯德管。48h后就可用于融合。如果不融合,每隔2-3天换液一次。或根据颜色(变黄)。待细胞帖壁长满单层后,必须传代,即弃掉旧培养液,加入3吸管新培养液,将帖壁细胞吹打混均,传3瓶。Take out the SP2/0 cell cryopreservation tube, immediately put it into a thermos bucket filled with 40°C water, and shake gently until the dynamic storage solution is completely dissolved, which should be completed within 1-2 minutes. Move the moving solution to a 15mL centrifuge tube, add 5mL culture medium, blow gently evenly, 1000rpm, 5min, discard the supernatant. Add 1 tube of culture solution with a Pasteur pipette, blow evenly, transfer it into a 50mL culture bottle, then add 2 pipette culture solution, blow evenly, and divide into two new 50mL culture bottles, so that the cells in one cryopreservation tube are divided into three 50mL culture flasks. Place them in an incubator containing 5% carbon dioxide at 37°C. Change the medium after 24h, 4 Pasteur tubes per bottle. It can be used for fusion after 48h. If not fused, change the medium every 2-3 days. Or according to color (turning yellow). After the cell wall is covered with a single layer, it must be subcultured, that is, the old culture medium is discarded, and new culture medium is added with 3 pipettes.
将培养72h的SP2/0用1640培养液悬浮,1000RPM离心10min,洗静细胞,共3次(每次用20mL)。用1640培养液悬浮,使细胞浓度为5×106/mL,体积2mL以上,供融合用。Suspend the SP2/0 cultured for 72 hours with 1640 culture medium, centrifuge at 1000 RPM for 10 minutes, and wash the cells, a total of 3 times (20 mL each time). Suspend with 1640 culture medium to make the cell concentration 5×10 6 /mL, and the volume is more than 2mL for fusion.
[实施例3]饲养细胞的制备[Example 3] Preparation of feeder cells
取12周龄以上,最好与骨髓瘤同系小鼠1-2只。挖去一只眼球放血,待血滴不出为止。拉颈处死,将鼠浸在75%酒精5min消毒。无菌条件下用消毒镊子和剪刀剪开小鼠腹部外层皮肤(切勿将腹膜剪破而使腹腔内液体流失)。然后向上下两侧方向拉开小鼠皮肤,暴露腹膜。用消毒注射器抽取3mL无血清HT1640培养液,用镊子将腹膜提起,将溶液注入小鼠腹腔内。一只手固定针筒,针头停留在腹腔内,清清按摩腹壁1-2min(使巨噬细胞游出),然后用注射器抽回腹腔内液体,并进行3次冲洗。收集冲洗液,1000rpm离心5min,弃上清。用HAT培养液(20%)稀释离心沉淀的细胞,并调整细胞浓度至1×105个/mL。将细胞悬液按每孔100ul(约两滴)铺板。放于37℃含5%的二氧化碳培养箱中培养。此细胞在融合前24h制备。Take 1-2 mice over 12 weeks old, preferably of the same strain as myeloma. One of the eyeballs was gouged out and the blood was let out until the blood dripped out. Kill by pulling the neck, and immerse the rat in 75% alcohol for 5 minutes for disinfection. Under aseptic conditions, use sterile forceps and scissors to cut the outer skin of the mouse abdomen (do not cut the peritoneum to cause fluid loss in the peritoneal cavity). The skin of the mouse was then pulled away in the direction of the upper and lower sides to expose the peritoneum. Draw 3 mL of serum-free HT1640 culture solution with a sterile syringe, lift the peritoneum with tweezers, and inject the solution into the mouse abdominal cavity. Fix the syringe with one hand, keep the needle in the abdominal cavity, massage the abdominal wall for 1-2 minutes (to make the macrophages swim out), then withdraw the intraperitoneal fluid with a syringe, and perform 3 flushes. Collect the washing solution, centrifuge at 1000rpm for 5min, and discard the supernatant. The centrifuged pelleted cells were diluted with HAT medium (20%), and the cell concentration was adjusted to 1×10 5 cells/mL. Plate the cell suspension at 100ul (about two drops) per well. Place them in an incubator containing 5% carbon dioxide at 37°C. The cells were prepared 24 h before fusion.
[实施例4]动物免疫[Example 4] Animal immunization
取8周龄雄性BALB/C小鼠,第一天使用弗氏完全佐剂乳化完全抗原,抗原佐剂比6∶4,注射后肢足垫20μl/脚,共40μl/鼠,抗原量为40μg/鼠;第三天待应激状态降低(可观察睾丸处状态,待肿大恢复正常)使用弗氏不完全佐剂乳化完全抗原,抗原佐剂比6∶4,注射后肢足垫30μl/脚,共60μl/鼠。抗原量为60μg/鼠;第15天检测血清效价,效价达到1∶3200以上。其中注射方法是采用1ml注射器,4.5号针头,在后足垫第二或三肉铺处进针,平行脚掌移动到脚掌中央处注射,注射完毕后停5秒钟,转动针头30度再出针。Take 8-week-old male BALB/C mice, use Freund's complete adjuvant to emulsify the complete antigen on the first day, the antigen-adjuvant ratio is 6:4, inject 20 μl/foot of the hind limb foot pad, a total of 40 μl/mouse, the amount of antigen is 40 μg/ Rats; on the third day, the stress state was reduced (the state of the testis can be observed, and the swelling returned to normal). The complete antigen was emulsified with Freund's incomplete adjuvant, the antigen-adjuvant ratio was 6:4, and 30 μl/foot was injected into the foot pad of the hind limb. A total of 60 μl/mouse. The amount of antigen was 60 μg/mouse; the serum titer was detected on the 15th day, and the titer reached above 1:3200. The injection method is to use a 1ml syringe with a 4.5-gauge needle, insert the needle at the second or third buttock of the rear foot pad, move parallel to the sole of the foot to the center of the sole of the foot for injection, stop for 5 seconds after the injection, turn the needle 30 degrees and then withdraw the needle .
[实施例5]腘淋巴细胞的获取[Example 5] Acquisition of Popliteal Lymphocytes
取实施例4被免疫小鼠摘取眼球获取血清于-20℃保存作为阳性对照,将鼠浸在75%酒精2min消毒。无菌条件下将小鼠后退基部剪开一小口,用钝头剪刀向两侧撑,使皮与肌肉分离,摘除腘淋巴结。平皿中加入5mL的1640培养液,腘淋巴结入其中,用注射器芯和铜网研磨腘淋巴结,以获得腘淋巴细胞。吹打均匀后,将细胞悬液依到试管中,并用1640培养液洗涤一次平皿。1000rpm离心10min,洗静腘淋巴细胞,共3次。用5mL1640培养液悬浮细胞,计数细胞。使细胞浓度为5×107个/mL,体积2mL以上。The eyeballs of the immunized mice in Example 4 were removed to obtain serum and stored at -20°C as a positive control, and the mice were sterilized by immersing them in 75% alcohol for 2 minutes. Under aseptic conditions, a small incision was made at the base of the back of the mouse, and the blunt-tip scissors were used to support the two sides to separate the skin from the muscle, and the popliteal lymph nodes were removed. Add 5mL of 1640 culture medium to the plate, put the popliteal lymph nodes into it, and grind the popliteal lymph nodes with a syringe core and copper mesh to obtain popliteal lymphocytes. After pipetting evenly, put the cell suspension into the test tube, and wash the plate once with 1640 culture medium. Centrifuge at 1000rpm for 10 minutes to wash the popliteal lymphocytes, a total of 3 times. Suspend the cells with 5mL1640 medium and count the cells. The cell concentration is 5×10 7 cells/mL, and the volume is more than 2 mL.
[实施例6]细胞融合及融合后细胞的培养[Example 6] Cell fusion and culture of cells after fusion
将实施例5所得腘淋巴细胞与实施例2所得SP2/0细胞(细胞数之比为10∶1)移到圆底玻璃离心管中,混均匀,1000rpm离心10min。弃掉上清后,用手指稍用力弹击试管底部,使沉淀呈桨糊状。迅速加入37℃预热的50%PEG(每1.0×108个淋巴细胞加0.2mLPEG)。巴断德吸管迅速吹打5-6次。加入PEG后30秒,700rpm离心3min。加入PEG后4分钟,加入RPMI1640培养液5mL,注意延管壁轻轻加,不要把细胞弄散。将试管低部划圆样运动2min,注意不要把细胞弄散。1000rpm离心10min,弃上清。重复洗细胞一次。小心加入5mLHT培养液,于室温放置30min。加含20%胎牛血清的RPMI1640-HAT培养液使SP2/0细胞为3.3×105个/mL,小心用巴斯德吸管吹打多次,使细胞均匀悬浮。分别加入到4块96孔培养版(每孔原有0.1mL饲养细胞)中,每孔0.1mL(约2滴),将培养版置于37℃含5%CO2培养箱中培养。The popliteal lymphocytes obtained in Example 5 and the SP2/0 cells obtained in Example 2 (the ratio of the number of cells is 10:1) were transferred to a round-bottomed glass centrifuge tube, mixed evenly, and centrifuged at 1000 rpm for 10 min. After discarding the supernatant, flick the bottom of the test tube slightly with your fingers to make the precipitate a paste. Add 50% PEG preheated at 37°C quickly (0.2 mL PEG per 1.0×10 8 lymphocytes). Quickly pipet 5-6 times with the Barnyard pipette. 30 seconds after adding PEG, centrifuge at 700rpm for 3min. 4 minutes after adding PEG, add 5 mL of RPMI1640 culture solution, pay attention to gently add along the tube wall, do not disperse the cells. Move the lower part of the test tube in a circular motion for 2 minutes, taking care not to disperse the cells. Centrifuge at 1000rpm for 10min, discard the supernatant. Repeat washing the cells one more time. Carefully add 5mL of HT culture solution and place at room temperature for 30min. Add RPMI1640-HAT culture medium containing 20% fetal bovine serum to make SP2/0 cells 3.3×10 5 cells/mL, carefully pipette several times with a Pasteur pipette to suspend the cells evenly. Add 0.1 mL (about 2 drops) to four 96-well culture plates (0.1 mL of feeder cells per well), and place the culture plates in a 37°C 5% CO 2 incubator for culture.
在培养过程中,采用半量换液法,即每次从每个小孔中吸出0.1mL培养液,再加入0.1mL新鲜培养液。第5、8和11天换以20%小牛血清HAT液,第14、18、22、25天换以20%小牛血清HT液During the cultivation process, the half-volume liquid replacement method was adopted, that is, 0.1 mL of culture liquid was aspirated from each small well each time, and 0.1 mL of fresh culture liquid was added. Change to 20% calf serum HAT solution on the 5th, 8th and 11th day, and change to 20% calf serum HT solution on the 14th, 18th, 22nd and 25th day
经3-5天的培养,单个的杂交瘤细胞开始长成几个或十几个细胞的集落,大多在8-10天时形成,个别至两周左右才能见到。当杂交瘤细胞集落的大小达到孔底面积的1/10时,就可检测上清液中的抗体,筛选出分泌抗体的杂交瘤细胞,并进行克隆化。第一次检测抗体在第二次换液的两天后,即融合后的第10天进行。以被测孔的OD值高于瘤细胞上清液对照OD值的2倍以上定为阳性。After 3-5 days of culture, a single hybridoma cell begins to grow into a colony of several or more than a dozen cells, most of which are formed in 8-10 days, and some can only be seen in about two weeks. When the size of the hybridoma cell colony reaches 1/10 of the bottom area of the well, the antibody in the supernatant can be detected, and the hybridoma cells secreting the antibody can be screened out and cloned. The first detection of antibody was carried out two days after the second change of medium, that is, on the 10th day after fusion. If the OD value of the tested well is more than 2 times higher than the OD value of the tumor cell supernatant control, it is regarded as positive.
[实施例7]阳性杂交瘤细胞的再克隆及扩大培养[Example 7] Re-cloning and expanded culture of positive hybridoma cells
待阳性孔细胞接近长满时,用含20%胎牛血清1的RPMI1640培养基将细胞轻轻吹起,吸到无菌小瓶中,细胞计数,稀释至每100μl中含有0.5-1个细胞密度。然后将稀释的细胞悬液滴入实施例2方法准备的饲养细胞培养板内,每孔100μl。将板置入5%CO2温箱37℃培养,每天观察一次,3天左右换液一次,观察每孔有几个克隆株,对有两个或没有细胞的孔分别作出标记,待克隆细胞生长至8-10天时,检测抗体,标出阳性孔,对所有的克隆细胞孔换液,换液2天后,再检测,将两次检测OD值高的孔进行对照,对两次检测都是阳性的孔再次克隆。直到克隆到所有的克隆细胞孔都为阳性,最后选择OD值高、细胞活力好杂交瘤细胞进行扩大培养。When the cells in the positive wells are nearly full, gently blow up the cells with RPMI1640 medium containing 20% fetal bovine serum 1, suck them into a sterile vial, count the cells, and dilute to a density of 0.5-1 cells per 100 μl . Then drop the diluted cell suspension into the feeder cell culture plate prepared by the method in Example 2, 100 μl per well. Place the plate in a 5% CO2 incubator at 37°C, observe once a day, change the medium once every 3 days, observe the number of clones in each well, and mark the wells with two or no cells respectively. When growing to 8-10 days, detect the antibody, mark the positive wells, change the medium for all the clonal cell wells, and test again after 2 days of changing the medium, and compare the wells with high OD values detected twice. Positive wells were cloned again. Until all cloned cell wells are positive, finally select hybridoma cells with high OD value and good cell viability for expansion culture.
[实施例8]腹水抗体的制备、纯化及亲和力测定[Example 8] Preparation, purification and affinity determination of ascites antibody
取8周龄BALB/C小鼠,腹腔注射液体石蜡0.4mL/只及福氏不完全佐剂0.2mL/只,8d后腹腔注射实施例7所得杂交瘤细胞2×106/只,接种7d后每天观察小鼠腹水产生情况,如腹腔明显鼓起,小鼠行动困难并且皮肤有紧张感,即用16号针头采集腹水,将腹水1000g/min离心10min,取上清,采用辛酸-饱和硫酸铵法初步纯化-20℃冻存备用。Take 8-week-old BALB/C mice, intraperitoneally inject 0.4 mL/mouse of liquid paraffin and 0.2 mL/mouse of Freund's incomplete adjuvant, 8 days later, intraperitoneally inject 2×10 6 hybridoma cells obtained in Example 7/mouse, and inoculate for 7 days Observe the occurrence of ascites in the mice every day. If the abdominal cavity is obviously swollen, the mice have difficulty moving and the skin feels tense, collect the ascites with a 16-gauge needle, centrifuge the ascites at 1000g/min for 10min, take the supernatant, and use octanoic acid-saturated sulfuric acid Preliminary purification by ammonium method and frozen at -20°C for future use.
腹水(纯化后腹水稀释至纯化前相同体积)分别从4000倍开始做2倍梯度稀释,同时以SP2/0细胞接种的腹水同等稀释度对照。Ascites (after purification, the ascites was diluted to the same volume as before purification) were serially diluted 2 times starting from 4000 times, and the same dilution of ascites inoculated with SP2/0 cells was used as a control.
采用非竞争性酶免疫法测定抗体亲和力。包被原(OVA-DA)按1、0.5、0.25、0.125μg/ml包被酶标板,100μl/孔,37℃,2h;1%的明胶封闭后,将单抗从4000倍开始倍比稀释。以抗体浓度(mol/L)的对数值为横座标,以其对应的OD值为纵座标,可在一个座标系内作出4条S形曲线。找出S曲线的顶部,设定为ODmax。在曲线中分别找出4条曲线各自50%ODmax对应的抗体浓度。将4个浓度两两一组,根据公式计算单抗的亲和常数。Antibody affinity was determined by non-competitive enzyme immunoassay. The coating agent (OVA-DA) was coated with 1, 0.5, 0.25, 0.125 μg/ml, 100 μl/well, 37°C, 2h; after blocking with 1% gelatin, the monoclonal antibody was multiplied from 4000 times dilution. Taking the logarithmic value of the antibody concentration (mol/L) as the abscissa and the corresponding OD value as the ordinate, four S-shaped curves can be drawn in one coordinate system. Find the top of the S-curve and set it as ODmax. Find the antibody concentrations corresponding to 50% ODmax of each of the four curves in the curves. The 4 concentrations were paired together, and the affinity constant of the monoclonal antibody was calculated according to the formula.
Ka=(n-1)/2(n[Ab`]t-[Ab]t)Ka=(n-1)/2(n[Ab`]t-[Ab]t)
注:n为每组中两个包被浓度的倍数,[Ab`]t和[Ab]t分别为每组中两个50%ODmax对应的抗体浓度(mol/L),Ka为亲和常数。Note: n is the multiple of the two coating concentrations in each group, [Ab`]t and [Ab]t are the two antibody concentrations (mol/L) corresponding to 50% ODmax in each group, and Ka is the affinity constant .
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNA2008100511317A CN101343322A (en) | 2008-08-29 | 2008-08-29 | A rapid immunization method for preparation of domoic acid monoclonal antibody |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNA2008100511317A CN101343322A (en) | 2008-08-29 | 2008-08-29 | A rapid immunization method for preparation of domoic acid monoclonal antibody |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101343322A true CN101343322A (en) | 2009-01-14 |
Family
ID=40245450
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2008100511317A Pending CN101343322A (en) | 2008-08-29 | 2008-08-29 | A rapid immunization method for preparation of domoic acid monoclonal antibody |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101343322A (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102539788A (en) * | 2012-01-13 | 2012-07-04 | 吉林大学 | Double-antibody sandwich ELISA (enzyme linked immuno-sorbent assay) test method for ovalbumin |
CN102680693A (en) * | 2012-05-18 | 2012-09-19 | 上海交通大学 | Domoic acid collaurum immunochromatographic test strip and preparation method thereof |
CN103898052A (en) * | 2012-12-24 | 2014-07-02 | 深圳先进技术研究院 | Preparation method of lymphocyte for cell fusion |
-
2008
- 2008-08-29 CN CNA2008100511317A patent/CN101343322A/en active Pending
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102539788A (en) * | 2012-01-13 | 2012-07-04 | 吉林大学 | Double-antibody sandwich ELISA (enzyme linked immuno-sorbent assay) test method for ovalbumin |
CN102539788B (en) * | 2012-01-13 | 2013-12-11 | 吉林大学 | Double-antibody sandwich ELISA (enzyme linked immuno-sorbent assay) test method for ovalbumin |
CN102680693A (en) * | 2012-05-18 | 2012-09-19 | 上海交通大学 | Domoic acid collaurum immunochromatographic test strip and preparation method thereof |
CN102680693B (en) * | 2012-05-18 | 2015-10-14 | 上海交通大学 | The preparation method of domoic acid colloidal gold immuno-chromatography test paper strip |
CN103898052A (en) * | 2012-12-24 | 2014-07-02 | 深圳先进技术研究院 | Preparation method of lymphocyte for cell fusion |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101831407B (en) | Hybridoma cell line of monoclonal antibody against African swine fever virus and secreted monoclonal antibody thereof | |
CN101818129B (en) | Hybridoma cell line for anti-African swine fever virus monoclonal antibody and monoclonal antibody secreted thereby | |
CN101825633B (en) | Competitive ELISA kit for detecting african swine fever virus antibody and purposes thereof | |
CN101833005B (en) | Competitive ELISA (Enzyme-Linked Immuno Sorbent Assay) kit for detecting antibody of African swine fever virus and application thereof | |
CN110642793A (en) | Azoxystrobin hapten, artificial antigen and antibody, and preparation method and application thereof | |
CN101597334A (en) | Monoclonal antibody of bluetongue virus (BTV) and preparation method and application | |
CN106434568B (en) | Porcine epidemic diarrhea virus resistant S protein hybridoma cell strain and application thereof | |
CN111849922A (en) | A kind of monoclonal antibody prepared from African swine fever virus truncated protein p54 and its application | |
CN102539788B (en) | Double-antibody sandwich ELISA (enzyme linked immuno-sorbent assay) test method for ovalbumin | |
CN101343322A (en) | A rapid immunization method for preparation of domoic acid monoclonal antibody | |
CN111943882A (en) | Pythium hapten, artificial antigen and antibody as well as preparation method and application thereof | |
CN110124027B (en) | Bovine rotavirus and bovine coronavirus bivalent inactivated vaccine and preparation method thereof | |
CN107012128A (en) | A kind of hybridoma cell strain for secreting aspergillus flavus resisting toxin B1 monoclonal antibodies and its application | |
CN107058242B (en) | Mouse anti-human CD61 monoclonal antibody hybridoma cell strain, monoclonal antibody, preparation method and application thereof, and flow detection reagent | |
CN104031152A (en) | Recombined pig/cow source escherichia coli heat stable enterotoxin fusion protein STp5-His, monoclonal antibody for resisting protein and application of protein | |
CN102181402B (en) | Monoclonal antibody of high-pathogenicity porcine reproductive and respiratory syndrome (PRRS) virus and preparation method thereof | |
CN101975855B (en) | Reagent and method for detecting efficacy on inactivated vaccine against duck infectious serositis | |
CN104560885B (en) | A kind of monoclonal antibody for resisting natural cattle gamma interferon, secretes hybridoma cell strain and the application of the antibody | |
CN102993300B (en) | Duck tembusu virus polyclonal antibody and preparation method thereof | |
CN102391993B (en) | Hybridoma cell strain 17C8 for detecting Brucella and monoclonal antibody generated by hybridoma cell strain | |
CN104130326A (en) | Monoclonal antibody of Chlamydophila abortus macrophage infectivity potentiator and hybridoma cell thereof | |
CN114891113A (en) | A kind of HRP-labeled mouse anti-Lin Musk IgG monoclonal antibody and preparation method thereof | |
CN102286431A (en) | Monoclonal antibody for resisting Japanese encephalitis virus (JEV) and application thereof | |
CN110791479B (en) | DEV gB protein monoclonal antibody and blocking ELISA kit for detecting DEV antibody | |
CN105925538B (en) | Hybridoma cell strain, synthetic cannabis sativa resistant monoclonal antibody generated by hybridoma cell strain and application of synthetic cannabis sativa resistant monoclonal antibody |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C12 | Rejection of a patent application after its publication | ||
RJ01 | Rejection of invention patent application after publication |
Open date: 20090114 |